v3.26.1
Segment Reporting
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company manages its business activities on a consolidated basis and operates as a single operating segment: Biotechnology. The accounting policies of the Biotechnology segment are the same as those described in Note 2 – Summary of Significant Accounting Policies.
The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer, Jung Soo Kim. The CODM uses net loss, as reported on its Consolidated Statements of Comprehensive (Loss) Income, in evaluating performance of the Biotechnology segment and determining how to allocate resources of the Company as a whole. The CODM does not review assets in evaluating the results of the Biotechnology segment, and therefore, such information is not presented.
The following table provides the operating financial results of the Biotechnology segment:
Three Months Ended
March 31,
2026
2025
Total revenues$— $— 
Significant segment expenses:
Research and development expense
312 808 
General and administrative expense
1,291 2,217 
Loss on disposal of assets
37 26 
Gain on lease termination
— (5,974)
Total operating expenses
1,640 (2,923)
Interest and dividend income
— 32 
Gain on settlement of accounts payable
— 191 
Change in fair value of contingent liability
(188)(136)
Total other income
(188)87 
Segment net (loss) income
$(1,828)$3,010